Mitochondrial DNA mutations-candidate biomarkers for breast cancer diagnosis in Bangladesh

作     者：Gazi Nurun Nahar Sultana Atiqur Rahman Abu Din Ahmed Shahinuzzaman Rowshan Ara Begum Chowdhury Faiz Hossain 

作者机构：Centre for Advanced Research in SciencesUniversity of DhakaDhaka 1000Bangladesh Department of MicrobiologyUniversity of DhakaDhaka 1000Bangladesh Department of Genetic Engineering and BiotechnologyUniversity of DhakaDhaka 1000Bangladesh National Cancer Research Institute and HospitalMohakhaliDhaka 1212Bangladesh East West UniversityMohakhaliDhaka 1212Banglades 

出 版 物：《Chinese Journal of Cancer》 (Chinese Journal of Cancer)

年 卷 期：2012年第31卷第9期

页      面：449-454页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by grants from the Centre for Advanced Research in Sciences(CARS) University of Dhaka 

主　　题：线粒体DNA突变 生物标志物 孟加拉国 乳腺癌 诊断 基因编码区 基因多态性 D-loop区 

摘      要：Breast cancer is a major health problem that affects more than 24% of women in Bangladesh. Furthermore, among low-income countries including Bangladesh, individuals have a high risk for developing breast cancer. This study aimed to identify candidate mitochondrial DNA (mtDNA) biomarkers for breast cancer diagnosis in Bangladeshi women to be used as a preventive approach. We screened the blood samples from 24 breast cancer patients and 20 healthy controls to detect polymorphisms in the D-loop and the ND3-and ND4-coding regions of mtDNA by direct sequencing. Among 14 distinct mutations, 10 polymorphisms were found in the D-loop, 3 were found in the ND3-coding region, and 1 was found in the ND4-coding region. The frequency of two novel polymorphisms in the D-loop, one at position 16290 (Tins) and the other at position 16293 (A-del), was higher in breast cancer patients than in control subjects (position 16290: odds ratio = 6.011, 95% confidence interval = 1.2482 to 28.8411, P = 0.002; position 16293: odds ratio = 5.6028, 95% confidence interval = 1.4357 to 21.8925, P = 0.010). We also observed one novel mutation in the ND3-coding region at position 10316 (A G) in 69% of breast cancer patients but not in control subjects. The study suggests that two novel polymorphisms in the D-loop may be candidate biomarkers for breast